EU For an earlier survey, see: 2014:1 KEI Research Note: Recent European Union Compulsory Licenses. 2014-03-01 DG-Enterprise – data exclusivity prevents access to life saving drugs (in the EU), even in an emergency situation, 2012-07-31 Germany German Court Issues Compulsory… Continue Reading
On Friday, 20 October 2017, India delivered the following intervention on compulsory licensing. India briefly recounted the experiences of Brazil, South Africa, and Thailand in using compulsory licensing to secure access to ARVs.
On Friday, 20 October 2017, Brazil delivered the following statement during TRIPS Council discussions on compulsory licensing. Brazil zeroed in a recent compulsory licensing case in Germany involving raltagravir, an antiretroviral.
On July 11, 2017, the German Federal Supreme Court announced that it had affirmed the decision of the Federal Patent Court last year to issue a compulsory license allowing Merck to continue selling its HIV drug, raltegravir (marketed as Isentress).
A German patent court has ordered a compulsory license under Section 24 of the Patent Act, allowing Merck (US) to continue to market the HIV drug raltegravir (marketed as Isentress).
